NeoGenomics has exercised its option to buy Inivata, a precision cancer diagnostics company that was formed to exploit Cambridge and CRUK research seven years ago.

Inivata, a UK-based precision cancer diagnostics spinout of University of Cambridge and Cancer Research UK, agreed to an acquisition by cancer diagnostics service provider NeoGenomics for $390m today.
NeoGenomics had supplied a $25m initial series C tranche in May 2020 as part of a strategic collaboration agreement that gave the corporate a fixed price option to purchase the spinout.
Founded in 2014, Inivata has created a liquid biopsy platform that can extract genomic information from a simple…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in